Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers is a research paper published in The Oncologist (2022). On theSindex it has a DataRank of 1.7. It has been cited 49 times, with 48 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.587
From this paper's citation signal
Citation Network Contribution
1.1
From 29 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 48 citers.
Cancer Center Support
Grant: P30CA008748
Health Research Board
Grant: CTIN-2021-001
Health Research Board
Grant: CTIC-2021-003
NCI
Bayer Healthcare and Loxo Oncology, Inc
NIH
Eli Lilly and Company
Keywords